Communications Biology (Apr 2021)
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
- Kushal Suryamohan,
- Devan Diwanji,
- Eric W. Stawiski,
- Ravi Gupta,
- Shane Miersch,
- Jiang Liu,
- Chao Chen,
- Ying-Ping Jiang,
- Frederic A. Fellouse,
- J. Fah Sathirapongsasuti,
- Patrick K. Albers,
- Tanneeru Deepak,
- Reza Saberianfar,
- Aakrosh Ratan,
- Gavin Washburn,
- Monika Mis,
- Devi Santhosh,
- Sneha Somasekar,
- G. H. Hiranjith,
- Derek Vargas,
- Sangeetha Mohan,
- Sameer Phalke,
- Boney Kuriakose,
- Aju Antony,
- Mart Ustav Jr,
- Stephan C. Schuster,
- Sachdev Sidhu,
- Jagath R. Junutula,
- Natalia Jura,
- Somasekar Seshagiri
Affiliations
- Kushal Suryamohan
- Research and Development Department, MedGenome Inc
- Devan Diwanji
- Cardiovascular Research Institute, University of California San Francisco
- Eric W. Stawiski
- Research and Development Department, MedGenome Inc
- Ravi Gupta
- MedGenome Labs Ltd.
- Shane Miersch
- Department of Molecular Genetics, and the Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto
- Jiang Liu
- ModMab Therapeutics
- Chao Chen
- Department of Molecular Genetics, and the Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto
- Ying-Ping Jiang
- ModMab Therapeutics
- Frederic A. Fellouse
- ModMab Therapeutics, Accelerator for Donnelly Collaboration, University of Toronto
- J. Fah Sathirapongsasuti
- Research and Development Department, MedGenome Inc
- Patrick K. Albers
- Wellcome Sanger Institute
- Tanneeru Deepak
- MedGenome Labs Ltd.
- Reza Saberianfar
- ModMab Therapeutics, Accelerator for Donnelly Collaboration, University of Toronto
- Aakrosh Ratan
- Center for Public Health Genomics, University of Virginia
- Gavin Washburn
- Research and Development Department, MedGenome Inc
- Monika Mis
- Research and Development Department, MedGenome Inc
- Devi Santhosh
- ModMab Therapeutics
- Sneha Somasekar
- Midwestern University
- G. H. Hiranjith
- Research and Development Department, MedGenome Inc
- Derek Vargas
- Research and Development Department, MedGenome Inc
- Sangeetha Mohan
- Department of Molecular Biology, SciGenom Labs Pvt Ltd
- Sameer Phalke
- Department of Molecular Biology, SciGenom Labs Pvt Ltd
- Boney Kuriakose
- AgriGenome Labs Private Ltd
- Aju Antony
- Department of Molecular Biology, SciGenom Labs Pvt Ltd
- Mart Ustav Jr
- Department of Molecular Genetics, and the Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto
- Stephan C. Schuster
- Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University
- Sachdev Sidhu
- Department of Molecular Genetics, and the Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto
- Jagath R. Junutula
- ModMab Therapeutics
- Natalia Jura
- Cardiovascular Research Institute, University of California San Francisco
- Somasekar Seshagiri
- ModMab Therapeutics
- DOI
- https://doi.org/10.1038/s42003-021-02030-3
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 11
Abstract
Suryamohan, Diwanji, Stawiski et al. identify natural ACE2 variants that are predicted to alter virus–host interactions. They find that soluble ACE2 K26R and T92I variants are more effective in blocking the entry of SARS-CoV-2 S-protein pseudotyped virus, compared to wild-type ACE2. This study suggests that ACE2 variants may modulate the host susceptibility to SARS-CoV-2.
